ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04^™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

ADvantage Therapeutics, Inc. announced that regulatory authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application to conduct a clinical trial on its lead candidate, AD04™ for the treatment of mild Alzheimer’s disease in each respective country.